Illumina Inc., a leading biotechnology company, has agreed to pay $9.8 million to settle allegations that it sold genomic sequencing systems with serious cybersecurity flaws to U.S. federal agencies.

"Illumina has inflicted substantial harm on Element, resulting in lost sales, diminished market share, and reduced profits," ...

Sept 22 (Reuters) - Life sciences company Element Biosciences sued Illumina (ILMN.O), opens new tab on Monday in separate cases in federal courts in California and ...